Medicine by Design's $4-million Pivotal Experiment Fund aims to bridge one of the critical gaps in the “valley of death” between a research discovery and a translatable therapy.
Competition aims to redefine regenerative medicine and ensure Toronto and Canada continue to lead the field for decades to come
Research to impact cancer, Alzheimer’s disease, autism, aneurysm and more.
Medicine by Design-funded researchers re-engineer enzyme that could help reverse damage from spinal cord injury and stroke
New version is more stable than the protein that occurs in nature, and could lead to new treatments for reversing nerve damage caused by traumatic injury or stroke.
$3 million investment to initiate answers to key questions that will transform health care
A team of researchers led by scientists at the University of Toronto has delayed the onset of amyotrophic lateral sclerosis (ALS) in mice. They are cautiously optimistic that this research, which was funded in part by a Medicine by Design 2018 New Ideas Award, combined with other clinical advances, points to a potential treatment for ALS in humans.
Medicine by Design supports coronavirus research through contribution to Toronto COVID-19 Action Fund
Thirty-one research projects at U of T and its affiliated hospitals selected for funding to contribute to the global fight against the novel coronavirus.
Medicine by Design Executive Director Michael Sefton elected to the U.S. National Academy of Engineering
U of T professor recognized for his accomplishments in tissue engineering